Judge Upholds Zyprexa Patent

Law360, New York (April 15, 2005, 12:00 AM EDT) -- In a major victory for Eli Lilly & Co., an Indiana federal judge has upheld the patent on the key ingredient on its $4.4 billion-a-year Zyprexa schizophrenia drug.

U.S. District Court Judge Richard Young's decision came down in Lilly's favor on all accounts, leaving in effect a patent on the schizophrenia drug Zyprexa that runs through April of 2011.

The decision to uphold the patent on the key ingredient in Zyprexa is a defeat for Ivax Corp., Dr. Reddy's Laboratories Ltd. and Teva Pharmaceutical Industries Ltd.,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.